Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various produ… Read more
Krebs Biochemicals and Industries Limited (KREBSBIO) - Total Assets
Latest total assets as of December 2025: ₹1.66 Billion INR
Based on the latest financial reports, Krebs Biochemicals and Industries Limited (KREBSBIO) holds total assets worth ₹1.66 Billion INR as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Krebs Biochemicals and Industries Limited - Total Assets Trend (2006–2025)
This chart illustrates how Krebs Biochemicals and Industries Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Krebs Biochemicals and Industries Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Krebs Biochemicals and Industries Limited's total assets of ₹1.66 Billion consist of 6.1% current assets and 93.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.1% |
| Accounts Receivable | ₹500.00K | 0.0% |
| Inventory | ₹60.31 Million | 3.6% |
| Property, Plant & Equipment | ₹1.46 Billion | 86.7% |
| Intangible Assets | ₹23.19 Million | 1.4% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Krebs Biochemicals and Industries Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Krebs Biochemicals and Industries Limited's current assets represent 6.1% of total assets in 2025, a decrease from 41.1% in 2006.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 0.2% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 17.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 86.7% of total assets.
Krebs Biochemicals and Industries Limited Competitors by Total Assets
Key competitors of Krebs Biochemicals and Industries Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Krebs Biochemicals and Industries Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Krebs Biochemicals and Industries Limited generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Krebs Biochemicals and Industries Limited is currently not profitable relative to its asset base.
Krebs Biochemicals and Industries Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.28 | 0.38 |
| Quick Ratio | 0.04 | 0.12 | 0.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹-1.02 Billion | ₹ -443.92 Million | ₹ -277.41 Million |
Krebs Biochemicals and Industries Limited - Advanced Valuation Insights
This section examines the relationship between Krebs Biochemicals and Industries Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | ₹1.69 Billion |
| Market Capitalization | $2.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Krebs Biochemicals and Industries Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Krebs Biochemicals and Industries Limited's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Krebs Biochemicals and Industries Limited (2006–2025)
The table below shows the annual total assets of Krebs Biochemicals and Industries Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹1.69 Billion | -5.13% |
| 2024-03-31 | ₹1.78 Billion | +1.82% |
| 2023-03-31 | ₹1.75 Billion | -7.81% |
| 2022-03-31 | ₹1.90 Billion | +19.21% |
| 2021-03-31 | ₹1.59 Billion | +19.00% |
| 2020-03-31 | ₹1.34 Billion | -6.02% |
| 2019-03-31 | ₹1.42 Billion | +13.10% |
| 2018-03-31 | ₹1.26 Billion | +3.11% |
| 2017-03-31 | ₹1.22 Billion | +4.86% |
| 2016-03-31 | ₹1.16 Billion | -2.58% |
| 2015-03-31 | ₹1.19 Billion | -13.27% |
| 2014-03-31 | ₹1.38 Billion | +0.11% |
| 2013-03-31 | ₹1.38 Billion | -7.38% |
| 2012-03-31 | ₹1.49 Billion | -5.25% |
| 2011-03-31 | ₹1.57 Billion | -2.26% |
| 2010-03-31 | ₹1.60 Billion | -34.33% |
| 2009-03-31 | ₹2.44 Billion | +21.93% |
| 2008-03-31 | ₹2.00 Billion | -5.68% |
| 2007-03-31 | ₹2.12 Billion | -8.73% |
| 2006-03-31 | ₹2.33 Billion | -- |